5 Stocks Pushing The Health Care Sector Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 1 points (-0.0%) at 13,971 as of Friday, Feb. 15, 2013, 11:49 AM ET. The NYSE advances/declines ratio sits at 1,429 issues advancing vs. 1,408 declining with 163 unchanged.

The Health Care sector currently is unchanged today versus the S&P 500, which is unchanged. On the negative front, top decliners within the sector include Agilent Technologies ( A), down 3.8%, Dr. Reddy Laboratories ( RDY), down 2.6%, Stryker Corporation ( SYK), down 1.0% and Thermo Fisher Scientific ( TMO), down 1.0%. Top gainers within the sector include Pharmacyclics Incorporated ( PCYC), up 5.1%, Biogen Idec ( BIIB), up 2.4%, Shire ( SHPG), up 2.3%, Novartis ( NVS), up 0.7% and AstraZeneca ( AZN), up 0.6%.

TheStreet Ratings group would like to highlight 5 stocks pushing the sector lower today:

5. DaVita HealthCare Partners ( DVA) is one of the companies pushing the Health Care sector lower today. As of noon trading, DaVita HealthCare Partners is down $2.17 (-1.8%) to $117.04 on average volume Thus far, 442,845 shares of DaVita HealthCare Partners exchanged hands as compared to its average daily volume of 1.0 million shares. The stock has ranged in price between $116.01-$118.50 after having opened the day at $118.47 as compared to the previous trading day's close of $119.21.

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. DaVita HealthCare Partners has a market cap of $11.3 billion and is part of the health services industry. The company has a P/E ratio of 21.5, above the S&P 500 P/E ratio of 17.7. Shares are up 7.4% year to date as of the close of trading on Thursday. Currently there are 10 analysts that rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, revenue growth, notable return on equity and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full DaVita HealthCare Partners Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

4. As of noon trading, Regeneron Pharmaceuticals ( REGN) is down $5.28 (-3.1%) to $163.96 on average volume Thus far, 440,989 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 863,000 shares. The stock has ranged in price between $163.25-$168.19 after having opened the day at $168.00 as compared to the previous trading day's close of $169.24.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States. Regeneron Pharmaceuticals has a market cap of $16.1 billion and is part of the drugs industry. The company has a P/E ratio of 86.5, above the S&P 500 P/E ratio of 17.7. Shares are down 0.4% year to date as of the close of trading on Thursday. Currently there are 7 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Regeneron Pharmaceuticals Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

3. As of noon trading, St Jude Medical ( STJ) is down $1.75 (-4.1%) to $41.26 on heavy volume Thus far, 4.0 million shares of St Jude Medical exchanged hands as compared to its average daily volume of 4.4 million shares. The stock has ranged in price between $40.82-$42.61 after having opened the day at $42.28 as compared to the previous trading day's close of $43.01.

St. Jude Medical, Inc. develops, manufactures, and distributes cardiovascular and implantable neurostimulation medical devices worldwide. It operates in four segments: Cardiac Rhythm Management, Cardiovascular, Atrial Fibrillation, and Neuromodulation. St Jude Medical has a market cap of $13.2 billion and is part of the health services industry. The company has a P/E ratio of 12.3, below the S&P 500 P/E ratio of 17.7. Shares are up 18.5% year to date as of the close of trading on Thursday. Currently there are 12 analysts that rate St Jude Medical a buy, no analysts rate it a sell, and 14 rate it a hold.

TheStreet Ratings rates St Jude Medical as a buy. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full St Jude Medical Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

2. As of noon trading, Medtronic ( MDT) is down $0.35 (-0.7%) to $46.82 on average volume Thus far, 2.4 million shares of Medtronic exchanged hands as compared to its average daily volume of 4.3 million shares. The stock has ranged in price between $46.63-$47.05 after having opened the day at $47.02 as compared to the previous trading day's close of $47.17.

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. Medtronic has a market cap of $47.5 billion and is part of the health services industry. The company has a P/E ratio of 15.2, below the S&P 500 P/E ratio of 17.7. Shares are up 14.6% year to date as of the close of trading on Thursday. Currently there are 11 analysts that rate Medtronic a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Medtronic as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, attractive valuation levels, solid stock price performance, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Medtronic Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

1. As of noon trading, Amgen ( AMGN) is down $0.76 (-0.9%) to $83.96 on average volume Thus far, 2.7 million shares of Amgen exchanged hands as compared to its average daily volume of 5.2 million shares. The stock has ranged in price between $83.62-$84.72 after having opened the day at $84.24 as compared to the previous trading day's close of $84.72.

Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. Amgen has a market cap of $65.2 billion and is part of the drugs industry. The company has a P/E ratio of 15.2, below the S&P 500 P/E ratio of 17.7. Shares are down 1.5% year to date as of the close of trading on Thursday. Currently there are 13 analysts that rate Amgen a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Amgen Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%